Read by QxMD icon Read

"Hepatitis C"

S Nematollahi, E Ayubi, A Almasi-Hashiani, K Mansori, Y Moradi, Y Veisani, E Jenabi, B Gholamaliei, S Khazaei
OBJECTIVES: Determination of the true burden of hepatitis C virus (HCV) infection among high-risk groups relies heavily on occurrence measures such as prevalence, which are vital for implementation of preventive action plans. Nevertheless, up-to-date data on the prevalence of HCV infection remain scarce in Iran. This study aimed to review the relevant literature systematically and determine the pooled prevalence of HCV infection among high-risk groups in Iran. STUDY DESIGN: Systematic review & meta-analysis...
June 20, 2018: Public Health
Manar-Aleslam M Mattar, Abdel-Rahman N Zekri, Nehal Hussein, Heba Morsy, Gamal Esmat, Magdy A Amin
Aim To determine the possible association between polymorphisms of DNA repair genes, including XRCC1 Arg194Tryp, Arg280His, and Arg399Glu, APE1 Asp148Glu, and NEIL2 Arg257Leu, and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). METHODS: A total of 264 subjects were recruited in this retrospective case-control study and were categorized into four groups: 88 control subjects (CR), 53 chronic hepatitis C patients (CHC), 36 liver cirrhotic patients (LC), and 87 HCC patients...
June 20, 2018: Gene
Alex Evangelista do Amaral, Michele Patrícia Rode, Julia Cisilotto, Telma Erotides da Silva, Josiane Fischer, Camila Matiollo, Elayne Cristina de Morais Rateke, Janaína Luz Narciso-Schiavon, Leonardo Lucca Schiavon, Tânia Beatriz Creczynski-Pasa
MicroRNAs (miRNAs) have remarkable potential as diagnostic and prognostic markers because of their roles in disease pathogenesis. miRNAs can be released into the bloodstream, where they are sufficiently stable to be detected noninvasively. Here, we prospectively evaluated serum levels of miR-21, miR-34a, miR-122, miR-181b, and miR-885-5p in patients with stable cirrhosis. Total RNA was extracted from the sera of patients with cirrhosis and healthy individuals, and the expression levels of the target miRNAs were analyzed by reverse transcription-quantitative polymerase chain reaction...
June 20, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
M Berenguer, K Agarwal, P Burra, M Manns, D Samuel
Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the post-transplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pre-transplant patients with advanced liver disease...
June 23, 2018: American Journal of Transplantation
Heba Omar, Mohamed Said, Rasha Eletreby, Mai Mehrez, Mohamed Bassam, Zeinab Abdellatif, Adel Hosny, Sherif Megawer, Mona El Amir, Ayman Yosry
Successful eradication of recurrent hepatitis C virus (HCV) infection following liver transplantation (HCV) improves graft survival. The current study aimed at evaluation of hepatic fibrosis changes among long term responders to DAAs therapy for recurrent HCV after liver transplantation using noninvasive methods. Patients with significant hepatic fibrosis (≥F2) who achieved SVR12 after treatment with DAAs for recurrent HCV were included (n=52). Hepatic fibrosis status was assessed, non-invasively, by calculation of fibrosis-4 score (FIB-4) and aspartate aminotransferase platelet ratio (APRI) index and by measurement of graft stiffness using FibroScan at baseline and 12- and 18-months post-treatment...
June 23, 2018: Clinical Transplantation
Hoda Alhamoudi, Nawras Alhalabi, Mouhammed Zein, Nazir Ibrahim
BACKGROUND AND STUDY AIMS: Liver disease caused by hepatitis C virus (HCV) is one of the most serious health issues worldwide. The prevalence of HCV among health care workers (HCWs) is higher than normal population. Our aim is to determine the seroprevalence of HCV among this high-risk group in Damascus Hospital, Syria in 2016. SUBJECTS AND METHODS: During March 2016, anonymous testing for HCV was offered to 150 residents and physicians from different departments (Surgery, otolaryngology, gastroenterology, anaesthesiology and laboratory) in Damascus Hospital using fourth-generation enzyme-linked immunosorbent assay (ELISA)...
June 19, 2018: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
Vishnu S Potluri, Roy D Bloom
In this issue, Alric and colleagues demonstrate through real-world experience that grazoprevir-elbasvir is safe and effective for treating hepatitis C in advanced kidney disease patients with higher comorbidity burdens. This commentary highlights that this and similar studies have primarily focused on treatment safety and efficacy, rather than the clinical impact of viral eradication. Critical knowledge gaps including which patients to treat, and when, as well as potential management strategies that may improve outcomes, are discussed...
July 2018: Kidney International
Amanda Abdel-Al, Eman El-Ahwany, Mona Zoheiry, Marwa Hassan, Amged Ouf, Hoda Abu-Taleb, Ali Abdel Rahim, Mohamed Darwish El-Talkawy, Suher Zada
BACKGROUND: Current methodologies used to determine the progression of hepatic fibrosis rely heavily on liver biopsy, a dangerous and invasive procedure, with semi-subjective analysis of the results of the biopsy. Thus, a new approach is immensely needed for monitoring the progression of liver fibrosis in Hepatitis C virus (HCV) patients. AIM OF WORK: The purpose of this study was to find highly specific and sensitive miRNA biomarkers that can be used to detect different stages of liver fibrosis...
June 19, 2018: Virus Research
Lisa M Boucher, Ahmed M Bayoumi, Amy E Mark, Curtis Cooper, Alana Martin, Zack Marshall, Rob Boyd, Pam Oickle, Nicola Diliso, Dave Pineau, Brad Renaud, Sean LeBlanc, Mark Tyndall, Olivia M Lee, Claire E Kendall
BACKGROUND: Chronic hepatitis C virus (HCV) infection is common among people who inject drugs (PWID) and is associated with morbidity and premature death. Although HCV can be cured, treatment may be inaccessible. We studied HCV testing, status and treatment among marginalized people who use drugs in Ottawa, Canada, a setting with universal insurance coverage for physician services. METHODS: We analyzed data from the Participatory Research in Ottawa: Understanding Drugs study, a cross-sectional, peer-administered survey of people who use drugs from 2012 to 2013...
June 22, 2018: Substance Use & Misuse
Maria Lina Tornesello, Clorinda Annunziata, Anna Lucia Tornesello, Luigi Buonaguro, Franco Maria Buonaguro
Viral oncogenesis is a multistep process largely depending on the complex interplay between viruses and host factors. The oncoviruses are capable of subverting the cell signaling machinery and metabolic pathways and exploit them for infection, replication, and persistence. Several viral oncoproteins are able to functionally inactivate the tumor suppressor p53, causing deregulated expression of many genes orchestrated by p53, such as those involved in apoptosis, DNA stability, and cell proliferation. The Epstein⁻Barr virus (EBV) BZLF1, the high-risk human papillomavirus (HPV) E6, and the hepatitis C virus (HCV) NS5 proteins have shown to directly bind to and degrade p53...
June 22, 2018: Cancers
C Sagnelli, C Uberti-Foppa, H Hasson, G Bellini, C Minichini, S Salpietro, E Messina, D Barbanotti, M Merli, F Punzo, N Coppola, A Lazzarin, E Sagnelli, F Rossi
OBJECTIVES: The aim of the study was to investigate whether the rs35761398 variants of the cannabinoid receptor 2 (CB2) gene may influence the acquisition of HIV infection and the clinical presentation of HIV/hepatitis C virus (HCV) coinfection. METHODS: We compared 166 HIV/HCV-coinfected patients with 186 HCV-monoinfected patients, all with biopsy-proven chronic hepatitis (using the Ishak scoring system), naïve for anti-HCV treatment and tested for the CB2 rs35761398 polymorphism (using the TaqMan assay)...
June 22, 2018: HIV Medicine
Chung-Feng Huang, Shu-Chi Wang, Ming-Lun Yeh, Ching-I Huang, Pei-Chien Tsai, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Angela Chen, Ming-Lung Yu
BACKGROUND/AIMS: MHC class I chain-related A (MICA) genetic variants and their serum levels (sMICA) were associated with the development of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) in untreated cohorts. The dynamic changes in serial sMICA levels and their association with HCC in the post-curative status is elusive. METHODS: Single nucleotide polymorphism rs2596542 of MICA and serial sMICA levels were analyzed in chronic hepatitis C (CHC) patients with a sustained virologic response after antivirals...
June 22, 2018: Journal of Gastroenterology and Hepatology
Ferhat Arslan, Bahadir Ceylan, Ahmet Riza Sahin, Özgür Günal, Bircan Kayaaslan, Kenan Uğurlu, Alpaslan Tanoğlu, Gülsen Iskender, Selma Tosun, Aynur Atilla, Fatma Sargin, Ayse Batirel, Ergenekon Karagöz, Abdullah Sonsuz, Ali Mert
In this study, we aimed to determine the late relapse rate in hepatitis C patients with sustained virological response after interferon-based regimens, and evaluated the predictors of late relapse while comparing the real-life data of our country with that of others. A multicenter retrospective study was performed to investigate the data of patients infected with HCV who obtained sustained virological response after classical or pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 48 weeks. Sustained virological response was based on negative HCV RNA level by PCR at the end of six months after the therapy...
June 1, 2018: Le Infezioni in Medicina
A Bocour, S K Greene, F Laraque, A Winters
Chronic hepatitis C virus (HCV) infection is the most common blood-borne infection in the USA. Estimating prevalence is critical for monitoring diagnosis, treatment, and cure and for allocating resources. Surveillance data reported to the New York City (NYC) Health Department, 2000-2015, were used to estimate HCV prevalence in NYC in 2015. The numbers who died, out-migrated or whose last RNA test was negative were removed from the count of people reported with HCV. A simulation model was used to remove estimates of people whose infection spontaneously cleared or was cured and to add an estimate of people unaware of infection...
June 22, 2018: Epidemiology and Infection
Cristina Alonso Madrigal, Manuela Dobón Rebollo, Viviana Laredo de la Torre, Luis Palomera Bernal, Francisco Agustín García Gil
INTRODUCTION: infection with the hepatitis C virus (HCV) causes significant morbidity and mortality in patients with hemophilia. Finally, patients are considered for a liver transplantation (LT) due to cirrhosis and/or hepatocellular carcinoma (HCC). MATERIAL AND METHODS: we report the cases of congenital coagulopathy and HCV infection that underwent LT in our institution. There were three patients with hemophilia A and one patient with von Willebrand disease (vWD) type 3...
June 22, 2018: Revista Española de Enfermedades Digestivas
Sern Wei Yeoh, Alex C N Holmes, Michael M Saling, Ian P Everall, Amanda J Nicoll
Patients with chronic hepatitis C virus (HCV) infection experience a range of symptoms including depression, fatigue and neurocognitive deficits, impairing quality of life. Depression, in particular, may be reactive to increased psychosocial stress, and the physical symptoms of advanced HCV or associated comorbidities. However, even patients at an early stage of HCV infection, with minimal hepatic inflammation or comorbidities, report more depressive symptoms and fatigue than the general population. Similarly, specific neurocognitive deficits occur in early stage HCV infection and are independent of the presence of depression or encephalopathy...
June 21, 2018: Hepatology International
Jonathan P Moorman, Matthew R Krolikowski, Stephanie M Mathis, Robert P Pack
PURPOSE OF REVIEW: The purpose of this review is to address infection with HIV and hepatitis C in the Appalachian region of the USA and the driving forces underlying this epidemic. We seek to discuss epidemiology of disease and the possible interventions to reduce incidence and burden of disease in this resource-limited area. RECENT FINDINGS: The rise of the opioid crisis has fueled a rise in new hepatitis C infection, and a rise in new HIV infection is expected to follow...
June 21, 2018: Current HIV/AIDS Reports
Narongsak Rungsakulkij, Wikran Suragul, Somkit Mingphruedhi, Pongsatorn Tangtawee, Paramin Muangkaew, Suraida Aeesoa
Background: To analyze prognostic factors following hepatic resection in patients with HBV-related hepatocellular carcinoma. Methods: We retrospectively analyzed 217 patients with HBV-related hepatocellular carcinoma who underwent hepatic resection at our hospital between January 2006 and December 2015. Disease-free survival and overall survival rates were analyzed using the Kaplan-Meier method and the log-rank test. The association between recurrence and survival and various clinicopathological factors, including serum alpha-fetoprotein (AFP) level, platelet count, platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, antiplatelet therapy, antiviral therapy, hepatitis C virus infection, and tumor-related characteristics, were assessed using univariate and multivariate logistic regression analysis...
2018: Infectious Agents and Cancer
Pei-Bin Zhai, Jie Qing, Ben Li, Lin-Qi Zhang, Lan Ma, Li Chen
NS3/4A serine protease is a prime target for direct-acting antiviral therapies against hepatitis C virus (HCV) infection. Several NS3/4A inhibitors have been widely used in clinic, while new inhibitors with better characteristics are still urgently needed. GP205 is a new macrocyclic inhibitor of NS3/4A with low nanomolar activities against HCV replicons of genotypes 1b, 2a, 4a, and 5a, with EC50 values ranging from 1.5 to 12.8 nmol/L. In resistance selection study in vitro, we found resistance-associated substitutions on D168: The activity of GP205 was significantly attenuated against 1b replicon with D168V or D168A mutation, similar as simeprevir...
June 21, 2018: Acta Pharmacologica Sinica
Lee-Won Chong, Chih-Chao Hsu, Chang-Yin Lee, Ruey-Hwang Chou, Cheng-Li Lin, Kuang-Hsi Chang, Yi-Chao Hsu
BACKGROUND: Bipolar disorder (BD), a type of psychiatric mood disorder, is manifested by chronic and recurrent mood fluctuations. This study aims to determine whether hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is a risk factor for BD. METHODS: A total of 48,215 patients with newly diagnosed viral hepatitis from 2000 to 2010 were identified and frequency-matched with 192,860 people without hepatitis. Both groups were followed until diagnosis with BD, withdrawal from the national health insurance program, or the end of 2011...
June 22, 2018: Journal of Translational Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"